Clinical Trials
8 trialsNCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT03746431 2026-01-07
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
Phase 1 Terminated
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT05576077 2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1 Terminated
NCT02315066 2022-04-21
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Phase 1 Completed
NCT03652077 2021-11-15
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT00002947 2014-07-02
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Yale University
Phase 1 Terminated
NCT00020579 2012-03-15
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed